10-Methyl-7-oxa-5,10,14,19,21,22,23-heptazatetracyclo[13.5.2.12,6.018,21]tricosa-1(20),2(23),3,5,15(22),16,18-heptaen-9-one

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 大环内酰胺类
• 英文名称: 10-Methyl-7-oxa-5,10,14,19,21,22,23-heptazatetracyclo[13.5.2.12,6.018,21]tricosa-1(20),2(23),3,5,15(22),16,18-heptaen-9-one
• 英文别名: 10-methyl-7-oxa-5,10,14,19,21,22,23-heptazatetracyclo[13.5.2.12,6.018,21]tricosa-1(20),2(23),3,5,15(22),16,18-heptaen-9-one
• 化学式: C₁₆H₁₇N₇O₂
• 分子量: 339.35
• InChiKey: VYJFMDSBDQOCFL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  25
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  97.5
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• MACROCYCLIC LRRK2 KINASE INHIBITORS
  申请人：ONCODESIGN S.A.

  公开号：US20140206683A1

  公开（公告）日：2014-07-24

  The present invention relates to novel macrocylic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of LRRK2 (Leucine-Rich Repeat Kinase 2). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine or diagnostic agent, in particular for the treatment and/or diagnosis of diseases characterized by LRRK2 kinase activity such as neurological disorders including Parkinson's disease and Alzheimer's disease.
• US9096609B2
  申请人：——

  公开号：US9096609B2

  公开（公告）日：2015-08-04
• US9370520B2
  申请人：——

  公开号：US9370520B2

  公开（公告）日：2016-06-21